doc_id,table_id,row_index,ColumnA,ColumnB,ColumnC,ColumnD,ColumnE,ColumnF
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,1,Examination,Baseline,2nd week from start of treatment (for Lzd containing regimens),Monthly,End of treatment,6 and 12 months posttreatment
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,2,Clinical evaluation by physician including weight/BMI,✓,✓,✓,✓,✓
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,3,Bacteriological tests,,,,,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,4,Smear microscopy,✓,,✓,✓,✓
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,5,TB culture,✓,,✓,✓,✓
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,6,Xpert MTB/XDR or First- and second-line LPA,✓,,If culture remains positive at month 4 of treatment in cases of culture reversion or culture positivity during post-treatment follow-up,If culture remains positive at month 4 of treatment in cases of culture reversion or culture positivity during post-treatment follow-up,If culture remains positive at month 4 of treatment in cases of culture reversion or culture positivity during post-treatment follow-up
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,7,Phenotypic DST,✓,,If culture remains positive at month 4 of treatment in cases of culture reversion or culture positivity during post-treatment follow-up,If culture remains positive at month 4 of treatment in cases of culture reversion or culture positivity during post-treatment follow-up,If culture remains positive at month 4 of treatment in cases of culture reversion or culture positivity during post-treatment follow-up
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,8,Diagnostic tests,,,,,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,9,Chest X-ray (Conduct every 6 months while on treatment),✓,,,✓,✓
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,10,"ECG (If regimen contains Bdq , Dlm , Pa, Mfx , Lfx or Cfz )",✓,,"In patients with preexisting cardiac disease and if the patient has any symptoms e.g. palpitations, dizziness or syncope",✓,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,11,Visual acuity and colour vision tests (If regimen contains Lzd or E),✓,✓,✓,✓,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,12,"Brief peripheral neuropathy screening (If regimen contains Lzd , H, Cs, Trd , Lfx , Mfx , or Am)",✓,✓,✓,✓,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,13,Mental health screening (PHQ-9),✓,,✓ (If Cs or Hh containing),✓,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,14,Blood chemistry / Haematological / Immunological tests,,,,,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,15,"Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (If regimen contains Z, H, Pa, Bdq , Eto/ Pto , Cs/ Trd , and PAS)",✓,,✓,✓,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,16,"CBC with platelet count (If regimen contains Lzd , Mpm , H and Pa)",✓,✓,✓,✓,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,17,Fasting blood sugar and/or glycosylated Hb (HbA1C),✓,,,,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,18,Serum potassium,✓,,,,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,19,Creatinine,✓,,✓ (If Am or S containing),,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,20,Thyroid-stimulating hormone,✓( If Pto / Eto or PAS containing and 3 monthly),,,,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,21,Albumin (If regimen contains Dlm ),✓,,,,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,22,Pregnancy test (For women of reproductive age),✓,,,,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,23,HIV screening,✓,,,,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,24,CD4 count (latest test if PLHIV),✓,,,,
WHO_TB_handbook_module4_treatment_2025,Table 2.9.2.,25,HBsAg and anti-HCV,✓,,,,